Join PfizerLink — a clinical research registry
Get notified about Pfizer clinical trials that may be right for you — now and over time.
Visit PfizerLink
To assess the safety and tolerability of increasing doses of PF-07104091 and to estimate the Maximum Tolerated Dose (MTD) and/or select the Recommended Phase 2 dose (RP2D) for PF-07104091 as a single agent in participants with advanced or metastatic small cell lung, breast and ovarian cancers.
Closest Location
Each clinical study has its own guidelines for who may participate, called eligibility criteria. These factors can include your age, sex, overall health, type and stage of disease, and personal treatment history. However, only the research study staff can determine if you qualify to enroll in the study.
Condition
Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
Sex
Male or Female
Age
18+ years